Kerrie-Anne Ho

Kerrie-Anne Ho

Auto-generated profile, based on publicly available information

Kerrie-Anne Ho

Community and Patient Preference Research Pty Ltd, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Journal of Affective Disorders
Verified
Journal Article
Closed access
KHKerrie-Anne Ho
Kerrie-Anne Ho
SBSiwei Bai
Siwei Bai
DMDonel Martin
Donel Martin
AAAngelo Alonzo
Angelo Alonzo
SDSocrates Dokos
Socrates Dokos
CLColleen K Loo
Colleen K Loo

19 December 2019 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
KHKerrie-Anne Ho
Kerrie-Anne Ho
MAMustafa Acar
Mustafa Acar
APAndrea Puig
Andrea Puig
GHGabor Hutas
Gabor Hutas
SFSimon Fifer
Simon Fifer
Background and objectives: The purpose of this study was to develop an understanding of treatment preferences in patients with inflammatory arthritis (IA) [rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA)] focussing on treatment attributes that patients’ value, their relative importance, and the risk-benefit trade-offs that characterise patients’ choices around treatment. Methods: A discrete choice experiment (DCE) approach was used. Attributes of interest were clinical efficacy; slowing of disease progression; risk of mild-moderate side effects; risk of severe side effects; frequency of administration; real-world product evidence; management of related conditions; and availability of a patient support programme. Using data from the DCE component, a restricted latent class model (LCM) was estimated to determine discrete ‘classes’ of treatment preferences. Results: In this analysis, 206 participants were included (AS n = 59; PsA n = 62; RA n = 85). Two classes were identified. For ‘class 1’ (59.9%), the most important attributes (across all treatment modalities) were preventing disease progression, clinical efficacy and risk of mild-to-moderate side effects. For ‘class 2’ (40.1%), clinical and non-clinical attributes were important, and attribute importance depended on treatment modality. Patient demographic and treatment characteristics did not predict class membership. Conclusion: For most patients with IA, clinical efficacy, stopping disease progression and risks of mild-to-moderate side effects are important treatment attributes. Patients with prior biologic DMARD experience had greater preference for injection treatments. For a subset of patients, patient support programmes and the frequency of administration were important. Clinicians should be mindful of preferences when prescribing treatment to patients with IA. Key Points• Most patients consider clinical efficacy, stopping disease progression and the risk of mild-to-moderate side effects as important treatment attributes• Patients with prior biologic DMARD experience have greater preference for injection treatments.• For a subset of patients, patient support programmes, and the frequency of administration were important.• Clinicians should be mindful of preferences when prescribing treatment to patients with IA.

1 March 2015 in Brain Stimulation
Verified
Journal Article
Closed access
TCTaariq A. Chew
Taariq A. Chew
KHKerrie-Anne Ho
Kerrie-Anne Ho
CLColleen K Loo
Colleen K Loo